Total Funding
51
14
Total FundingSeries B raised
Growth Score 51 in past quarter
-6 pts
Heat Score 14 in past quarter
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
27791
Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.
- Stephen Cunningham: Co-Founder ,Executive VP & Chief Development Officer
Paul Cayer: CFOPast Role: Verus Pharmaceuticals, Senior Vice President & Corporate Development
About the Company
Engrail is forging a new direction to reduce the enormous burden of diseases that impact the nervous system. We unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage
our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.
